Webinars and podcasts
Webinars and podcasts are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Webinars
Nature: Using synthetic VHH to optimize T-cell mediated immunotherapies
This webinar summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.
Bispecific Discovery: where do we start – and where are we going?
This webinar covers the unique characteristics of VHH, including high stability, comparable affinity to standard IgGs and their flexibility in terms of generating multi-specific therapeutics. These properties, combined with Isogenica’s humanised, CMC-liability free VHH libraries allows us to generate novel multi-specifics at unmatched speed and quality.
What Makes Cancer so Hard?
Why is Cancer so Hard? Claudia Fernandes tells us her thoughts…
In our second edition of Why is Cancer so Hard? we chat to Claudia Fernandes, Alliances Manager, about her take on why cancer is so difficult to treat and, eventually, cure:
Why is Cancer so Hard? Marion Cubbitt tells us her thoughts…
Researchers have been trying to fight cancer for over 100 years, yet there’s still no cure. What makes treating cancer so challenging? We asked our Director of Discovery for her views…